Federica Carucci

Federica Carucci

Auto-generated profile, based on publicly available information

Federica Carucci


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
IMIvan Mercurio
Ivan Mercurio
FCFederica Carucci
Federica Carucci
VNVittoria Nanna
Vittoria Nanna
SMSara Di Marino
Sara Di Marino
MPMaria Giovanna Eva Papadopoulos
Maria Giovanna Eva Papadopoulos
DADomenico Alberga
Domenico Alberga
Phosphoprotein Enriched in Diabetes/Astrocytes 15 (PED/PEA-15) is a 15 kDa adaptor protein whose overexpression drives tumorigenesis and type II diabetes through dysregulated protein-protein interactions (PPIs) mediated by its Death Effector Domain (DED). Despite its therapeutic relevance, no potent small-molecule inhibitors targeting the DED have yet been identified. Here, we employed a fragment-based drug discovery approach combining 19F and 1H NMR screening of a 118-compound fluorinated library to identify F2 a fragment that binds the PED/PEA-15 DED with an estimated dissociation constant of 150 μM. NMR chemical shift perturbation analysis mapped the binding site to the α2-α3 loop, α3, and α5 helices. To better characterise the protein, Small-angle X-ray scattering of the apo protein was employed, yielding a structural model in which the C-terminal tail is consistent with a conformation that is not maximally extended. Induced fit docking and molecular dynamics simulations of the PED/PEA-15-F2 complex supported a plausible binding pose and suggested a ligand-induced destabilisation of the α3 helix propagating to the α6 helix. Correlation network analysis further suggests a hypothesis in which F2 rewires the dynamic architecture of the DED and alters allosteric communication between residues of the DED and the C-terminal tail. The identification of a ligand-accessible site on the DED supports the druggability of PED/PEA-15 and provides a refined structural framework for fragment optimisation and for testing whether engagement of this site can be translated into modulation of PED/PEA-15 PPIs with therapeutic potential in cancer and type II diabetes.